Abstract
Acne vulgaris is a chronic inflammatory skin disease mainly affecting adolescents and young adults. When evaluating the acne patient, the questions arise of whether laboratory evaluations are justified for acne vulgaris either in terms of diagnosis, monitoring during treatment, or for a hormonal work-up. This chapter addresses these questions aiming to provide available scientific data regarding laboratory evaluations for acne.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in acne Group. J Am Acad Dermatol. 2009;60:s1–50.
Antoniou C, Dessinioti C, Stratigos AJ, Katsambas A. Clinical and therapeutic approach in childhood acne: an update. Pediatr Dermatol. 2009;26:373–80.
Darley CR, Moore JW, Besser GM, et al. Androgen status in women with late onset or persistent acne vulgaris. Clin Exp Dermatol. 1984;9:28–35.
Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 1983;81:70–4.
Mathur RS, Moody LO, Landgrebe S, et al. Plasma androgens and sex hormone binding globulin in the evaluation of hirsute females. Fertil Steril. 1981;35:296–305.
Schiavone FE, Rietschel RL, Sgoutas D, et al. Elevated free testosterone levels in women with acne. Arch Dermatol. 1983;119:799–802.
Scholl GM, Wu CH, Leyden J. Androgen excess in women with acne. Obstet Gynecol. 1984;64:683–8.
Carmina E, Lobo RA. Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab. 1993;76:1111–4.
Odlind V, Carlstrom K, Michaelsson C, et al. Plasma androgenic activity in women with acne vulgaris and in healthy girls before, during and after puberty. Clin Endrocrinol. 1982;16:243–9.
Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28:17–23.
Caputo V, Fiorella S, Curiale S, et al. Refractory acne and 21-hydroxylase deficiency in a selected group of female patients. Dermatology. 2010;220:121–7.
Placzek M, Arnold B, Schmidt H, et al. Elevated 17-hydroxyprogesterone serum values in male patients with acne. J Am Acad Dermatol. 2005;53:955–8.
Dessinioti C, Katsambas A. Congenital adrenal hyperplasia. Dermatoendocrinology. 2009;1:86–90.
Chen W, Obermayer-Pietsch B, Hong JB, et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol. 2011;25:637–46.
Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol. 1989;121:675–80.
Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671–83.
Gollnick H, Cunliffe W, Berson D, et al. Management of acne. J Am Acad Dermatol. 2003;49:S20–25.
Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21:86–95.
Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology. 2000;200:223–31.
Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol. 2007;157:540–6.
Schaffer JV, Davidson DM, McNiff JM, et al. Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol. 2001;44:198–206.
Gait RC, Affleck AG, Leach IH, et al. Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris. J Am Acad Dermatol. 2008;58(5 suppl 1):s123–4.
Akin E, Miller LC, Tucker LB. Minocycline-induced lupusin adolescents. Pediatrics. 1998;101:926–8.
Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunologic study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med. 1998;105:484–7.
Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol. 2000;142:461–7.
Shapiro LE, Uetrecht J, Shear NH. Minocycline, perinuclear antineutrophilic cytoplasmic antibody, and pigment: the biochemical basis. J Am Acad Dermatol. 2001;45:787–9.
Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol. 2004;22:412–8.
Friedman SJ. Leukopenia and neutropenia is associated with isotretinoin therapy. Arch Dermatol. 1987;123:293–5.
Moeller KE, Touma SC. Prolonged thrombocytopenia associated with isotretinoin. Ann Pharmacutter. 2003;37:1622–4.
Alcalay J, Landau M, Zucker A. Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests? J Dermatol Treat. 2001;12:9–12.
Warren KJ, Cruz PD. Clinical outcome and cost analysis of isotretinoin versus conventional regiments in the treatment of moderate acne vulgaris in male patients. Pediatr Dermatol. 1998;15:329–31.
Altman RS, Altman LJ. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgatis. Dermatology. 2002;204:232–5.
Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol. 1994;131:360–3.
Lebucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology. 1993;186:123–8.
Layton AM, Knaggs H, Taylor J, et al. Isotretinoin for acne vulgaris. Ten years later. A safe and successful treatment. Br J Dermatol. 1993;129:292–6.
Stainforth JM, Layton AM, Taylor JP, et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol. 1993;129:297–301.
Lester RS, Schachter GD, Light MJ. Isotretionin and tetracycline in the management of severe nodulocystic acne. Int J Dermatol. 1985;24:252–7.
Cunliffe WJ, van der Kerkhof PC, Caputo R, et al. Roaccutane: treatment guidelines: results of international survey. Dermatology. 1997;194:351–7.
Ortonne JP. Oral isotretinoin treatment policy: do we all agree? Dermatology. 1997;195 Suppl 1:34–7. discussion 38–40.
Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J Dermatol Treat. 2006;17:214–6.
Baxter KF, Ling TC, Barth JH, et al. Retrospective survey of serum lipids in patients receiving more than three courses of isotretinoin. J Dermatol Treat. 2003;14:216–8.
Johnson TM, Rapini RP. Isotretinoin-induced thrombocytopenia. J Am Acad Dermatol. 1987;17:838–9.
Michaelsson G, Vahlquist A, Mobacken H, et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol. 1986;66:144–8.
Zane LT, Leyden WA, Marqueling AL, et al. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142:1016–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dessinioti, C., Zouboulis, C.C. (2014). Laboratory Evaluations in Acne. In: Zouboulis, C., Katsambas, A., Kligman, A. (eds) Pathogenesis and Treatment of Acne and Rosacea. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69375-8_50
Download citation
DOI: https://doi.org/10.1007/978-3-540-69375-8_50
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69374-1
Online ISBN: 978-3-540-69375-8
eBook Packages: MedicineMedicine (R0)